Berkshire Hathaway's (NYSE: BRKA) (NYSE: BRKB) second-quarter 13F is now officially filed, disclosing all the stock trades it made during the quarter, and ultimately offering a snapshot of the conglomerate's current stock portfolio. No real surprises either. Although Berkshire was a net buyer for the first time in a long time, the additions were expansions of existing positions, or new purchases that make enough sense.
This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia.
Continue » There's one name arguably worth Warren Buffett's and Greg Abel's consideration, however, that still isn't a Berkshire Hathaway holding. That's drugmaker Pfizer (NYSE: PFE). Here's why Berkshire should buy it, and why you might want to even if Abel or Buffett don't end up adding it to Berkshire Hathaway's portfolio anytime soon.
If you know anything at all about Pfizer, then you might disagree with the call. This pharmaceutical stock has underperformed since peeling back from its COVID-prompted peak in late 2021. In fact, it's gone nowhere since early 2024, unable to offset the massive revenue decline resulting from the wind-down of the coronavirus pandemic.
The company wasn't able to do a great deal of developmental work during that period; shareholders have paid the price in the meantime. Now take a step back and take an intellectually honest look at the bigger picture. While not perfect (no prospective investment is), the market may be so fixated on Pfizer's recent past that it's struggling to see its plausible future.
Through a handful of acquisitions like the purchase of Arena Pharmaceuticals in 2022, its 2023 deal for Seagen, and the acquisition of Metsera in 2025, the company's reloaded its pipeline. It's particularly got a bunch of new oncology drugs like Seagen's Padcev and Tivdak, and hopes to leverage its current portfolio of drugs and new know-how to develop at least eight new blockbuster (annual revenue in excess of $1 billion) cancer treatments by 2030. Meanwhile, its deal for Metsera puts it deep in the GLP-1 weight-loss-drug race with a potential option that's distinctly different than most others already on the market.
Extract — continue reading at the source.
